1. Home
  2. PDT vs SLBT Comparison

PDT vs SLBT Comparison

Compare PDT & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Premium Dividend Fund

PDT

John Hancock Premium Dividend Fund

N/A

Current Price

$11.55

Market Cap

581.9M

Sector

Finance

ML Signal

N/A

Logo SL Science Holding Limited Ordinary Shares

SLBT

SL Science Holding Limited Ordinary Shares

N/A

Current Price

$0.54

Market Cap

644.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PDT
SLBT
Founded
N/A
N/A
Country
United States
Taiwan
Employees
N/A
N/A
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
581.9M
644.9M
IPO Year
1994
2025

Fundamental Metrics

Financial Performance
Metric
PDT
SLBT
Price
$11.55
$0.54
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 136.0K
46.5K
Earning Date
01-01-0001
10-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.49
$0.57
52 Week High
$13.65
$6.25

Technical Indicators

Market Signals
Indicator
PDT
SLBT
Relative Strength Index (RSI) 32.10 22.09
Support Level $11.49 N/A
Resistance Level $13.02 $1.75
Average True Range (ATR) 0.17 0.13
MACD -0.05 -0.01
Stochastic Oscillator 1.34 4.94

Price Performance

Historical Comparison
PDT
SLBT

About PDT John Hancock Premium Dividend Fund

John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest capital growth. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.

About SLBT SL Science Holding Limited Ordinary Shares

SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.

Share on Social Networks: